loading
Precedente Chiudi:
$124.38
Aprire:
$123.45
Volume 24 ore:
7,450
Relative Volume:
0.01
Capitalizzazione di mercato:
$7.43B
Reddito:
$343.51M
Utile/perdita netta:
$-530.29M
Rapporto P/E:
-10.97
EPS:
-11.3176
Flusso di cassa netto:
$-610.17M
1 W Prestazione:
-1.14%
1M Prestazione:
-4.50%
6M Prestazione:
+0.01%
1 anno Prestazione:
+31.55%
Intervallo 1D:
Value
$122.42
$124.09
Intervallo di 1 settimana:
Value
$118.05
$133.00
Portata 52W:
Value
$90.13
$161.00

Ascendis Pharma A S Adr Stock (ASND) Company Profile

Name
Nome
Ascendis Pharma A S Adr
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
879
Name
Cinguettio
Name
Prossima data di guadagno
2024-12-13
Name
Ultimi documenti SEC
Name
ASND's Discussions on Twitter

Confronta ASND con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
ASND 123.47 7.43B 343.51M -530.29M -610.17M -11.32
VRTX 447.95 115.74B 10.63B -479.80M -1.35B 13.33
REGN 741.90 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 589.67 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.92 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.56 24.49B 3.30B -501.07M 1.03B 11.54

Ascendis Pharma A S Adr Stock (ASND) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-12-20 Iniziato Jefferies Buy
2023-06-14 Ripresa Credit Suisse Neutral
2023-04-05 Downgrade Oppenheimer Outperform → Perform
2023-04-04 Downgrade Morgan Stanley Overweight → Equal-Weight
2023-04-03 Downgrade Credit Suisse Outperform → Neutral
2022-10-20 Iniziato Goldman Buy
2022-08-30 Ripresa Berenberg Buy
2022-03-28 Ripresa Wedbush Outperform
2022-03-15 Aggiornamento BofA Securities Neutral → Buy
2022-03-01 Iniziato Citigroup Buy
2022-02-14 Aggiornamento Oppenheimer Perform → Outperform
2022-01-06 Iniziato Cowen Market Perform
2021-12-08 Iniziato Wells Fargo Overweight
2021-10-20 Downgrade BofA Securities Buy → Neutral
2021-03-30 Downgrade Oppenheimer Outperform → Perform
2021-03-11 Ripresa Stifel Buy
2020-12-17 Iniziato Berenberg Buy
2020-09-14 Ripresa JP Morgan Overweight
2020-03-20 Iniziato Oppenheimer Outperform
2019-10-11 Iniziato Morgan Stanley Overweight
2019-03-25 Iniziato Evercore ISI Outperform
2019-01-24 Iniziato Cantor Fitzgerald Overweight
2019-01-24 Aggiornamento Leerink Partners Mkt Perform → Outperform
2018-06-26 Iniziato Stifel Buy
2018-04-02 Reiterato Leerink Partners Mkt Perform
2017-05-11 Iniziato JP Morgan Overweight
2017-03-09 Downgrade Leerink Partners Outperform → Mkt Perform
2017-02-09 Iniziato Credit Suisse Outperform
2016-09-26 Iniziato Wedbush Outperform
Mostra tutto

Ascendis Pharma A S Adr Borsa (ASND) Ultime notizie

pulisher
Nov 20, 2024

European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

European Equities Traded in the US as American Depositary Move Higher in Monday Trading - MSN

Nov 20, 2024
pulisher
Nov 04, 2024

Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug - Benzinga

Nov 04, 2024
pulisher
Oct 21, 2024

TD Cowen boosts Ascendis stock target, sees Q3 Skytrofa growth lagging but long-term outlook intact - Investing.com

Oct 21, 2024
pulisher
Oct 14, 2024

Nothing is Better Than Ascendis Pharma A/S ADR (ASND) stock at the moment - SETE News

Oct 14, 2024
pulisher
Oct 14, 2024

Financial Health Report: Ascendis Pharma A/S ADR (ASND)’s Ratios Tell a Tale - The Dwinnex

Oct 14, 2024
pulisher
Oct 09, 2024

Ascendis Pharma A/S ADR’s Banking’s 100-Day Moving Average at 134.03: Will the Stock Break Through? - The InvestChronicle

Oct 09, 2024
pulisher
Oct 09, 2024

Stock Market Recap: Ascendis Pharma A/S ADR (ASND) Concludes at 132.05, a -5.10 Surge/Decline - The Dwinnex

Oct 09, 2024
pulisher
Oct 03, 2024

The Ascendis Pharma A/S ADR (ASND) had a good session last reading, didn’t it? - US Post News

Oct 03, 2024
pulisher
Oct 01, 2024

Stocks Showing Rising Market Leadership: Ascendis Pharma ADR Earns 83 RS Rating - Investor's Business Daily

Oct 01, 2024
pulisher
Sep 30, 2024

Top investors say Ascendis Pharma A/S ADR (ASND) ticks everything they need - SETE News

Sep 30, 2024
pulisher
Sep 30, 2024

Ascendis reports positive 3-year hypoparathyroidism trial data - Investing.com

Sep 30, 2024
pulisher
Sep 25, 2024

Results from Ascendis Pharma A/S ADR (ASND) show risk - US Post News

Sep 25, 2024
pulisher
Sep 24, 2024

Sei Investments Co. Sells 81,615 Shares of Ascendis Pharma A/S (NASDAQ:ASND) - MarketBeat

Sep 24, 2024
pulisher
Sep 23, 2024

Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $191.00 - MarketBeat

Sep 23, 2024
pulisher
Sep 22, 2024

Ascendis Pharma A/S (NASDAQ:ASND) Holdings Lifted by Evolutionary Tree Capital Management LLC - MarketBeat

Sep 22, 2024
pulisher
Sep 19, 2024

European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - MSN

Sep 19, 2024
pulisher
Sep 19, 2024

Investor’s Delight: Ascendis Pharma A/S ADR (ASND) Closes Strong at 148.88, Up 1.56 - The Dwinnex

Sep 19, 2024
pulisher
Sep 19, 2024

Ascendis Pharma launches $300 million public offering - Investing.com

Sep 19, 2024
pulisher
Sep 19, 2024

Ascendis Pharma A/S (NASDAQ:ASND) Shares Acquired by Seven Eight Capital LP - MarketBeat

Sep 19, 2024
pulisher
Sep 18, 2024

Analysts review Ascendis Pharma A/S ADR’s rating - Knox Daily

Sep 18, 2024
pulisher
Sep 18, 2024

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs - Yahoo Finance

Sep 18, 2024
pulisher
Sep 18, 2024

Analyzing Edgewise Therapeutics Inc (EWTX) After Recent Trading Activity - Knox Daily

Sep 18, 2024
pulisher
Sep 18, 2024

Ascendis Pharma A/S ADR (ASND) did well last session? - US Post News

Sep 18, 2024
pulisher
Sep 17, 2024

Ascendis Pharma shares retain Outperform rating, Evercore ISI lifts target citing potential in new patient starts - Investing.com

Sep 17, 2024
pulisher
Sep 17, 2024

Prepare Yourself for Liftoff: Ascendis Pharma A/S ADR (ASND) - SETE News

Sep 17, 2024
pulisher
Sep 17, 2024

Oppenheimer raises Ascendis Pharma shares, maintains Outperform rating - Investing.com India

Sep 17, 2024
pulisher
Sep 16, 2024

Goldman Sachs raises Ascendis Pharma stock price target on study success - Investing.com India

Sep 16, 2024
pulisher
Sep 16, 2024

Jefferies lifts Ascendis Pharma target to $179 on trial data - Investing.com

Sep 16, 2024
pulisher
Sep 16, 2024

Barclays maintains BioMarin at Overweight with $110 target - Investing.com

Sep 16, 2024
pulisher
Sep 16, 2024

Why This Small Biotech Is Hammering BioMarin Today - Investor's Business Daily

Sep 16, 2024
pulisher
Sep 16, 2024

Positive topline data supports Ascendis Pharma stock, analyst highlights potential for weekly injection advantage. - Investing.com India

Sep 16, 2024
pulisher
Sep 16, 2024

Ascendis Pharma reaffirms stock target, buy rating on study success - Investing.com

Sep 16, 2024
pulisher
Sep 16, 2024

Ascendis Pharma reports growth in achondroplasia trial - Investing.com India

Sep 16, 2024
pulisher
Sep 13, 2024

Citi maintains buy on Ascendis with $178 target amid trial data - Investing.com

Sep 13, 2024
pulisher
Sep 13, 2024

Market Insights: Ascendis Pharma A/S ADR (ASND)’s Notable Gain of 0.78, Closing at 113.81 - The Dwinnex

Sep 13, 2024
pulisher
Sep 12, 2024

Ascendis Pharma A/S ADR (ASND)’s highs and lows: A closer look at its stock price fluctuations - US Post News

Sep 12, 2024
pulisher
Sep 10, 2024

Closing Figures Unveiled: Ascendis Pharma A/S ADR (ASND) Drop -1.94, Closes at 116.84 - The Dwinnex

Sep 10, 2024
pulisher
Sep 10, 2024

Citi maintains Ascendis Pharma stock at Buy, positive outlook ahead of pivotal trial data - Investing.com India

Sep 10, 2024
pulisher
Sep 09, 2024

A better buy-in window may exist right now for Ascendis Pharma A/S ADR (ASND) - SETE News

Sep 09, 2024
pulisher
Sep 08, 2024

European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading - MSN

Sep 08, 2024
pulisher
Sep 06, 2024

TD Cowen maintains Buy on Ascendis, keeps $157 target - Investing.com

Sep 06, 2024
pulisher
Sep 06, 2024

Ascendis Pharma A/S ADR (ASND) requires closer examination - US Post News

Sep 06, 2024
pulisher
Sep 05, 2024

Stock Performance Spotlight: Ascendis Pharma A/S ADR (ASND) Ends the Day at 119.50, Down by -11.27 - The Dwinnex

Sep 05, 2024
pulisher
Sep 04, 2024

Jefferies cuts Ascendis share price target amid hGH market pressure - Investing.com

Sep 04, 2024
pulisher
Sep 04, 2024

Goldman Sachs cuts Ascendis Pharma shares target, maintains Buy rating - Investing.com

Sep 04, 2024
pulisher
Sep 04, 2024

Ascendis Pharma stock target cut, retains rating amid Skytrofa sales miss - Investing.com

Sep 04, 2024
pulisher
Sep 04, 2024

Earnings call: Ascendis Pharma reports mixed Q2 2024 results, forecasts growth - Investing.com

Sep 04, 2024
pulisher
Sep 04, 2024

Biotech Makes A Bearish Move On Drug-Pricing Fiasco - Investor's Business Daily

Sep 04, 2024
pulisher
Sep 04, 2024

Taking on analysts’ expectations and winning: Ascendis Pharma A/S ADR (ASND) - SETE News

Sep 04, 2024

Ascendis Pharma A S Adr Azioni (ASND) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):